Albireo Pharma NASDAQ:ALBO is reporting this earnings, what to expect.

1
580

Albireo Pharma NASDAQ:ALBO is reporting this earnings, what to expect.

Albireo Pharma NASDAQ:ALBO headquartered in Danbury, Connecticut, United States is reporting their earnings on 05/17/2018 before the bell. Street forecast for the quarter ending March 2018 is $3.75.

According to stock market daily analyst this is Lower then same time previous year. Albireo Pharma, reported EPS for the same quarter last year was $-1.06.

()
()

Chart

Overview of Albireo Pharma NASDAQ:ALBO

Albireo is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs. Our parent company, Albireo Pharma, Inc., is located in Boston, Massachusetts and our key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. We were spun out from AstraZeneca in 2008.

ALBO
Change
% Change
Market Cap
% Change from 52 Week Low
% Change from 52 Week High
Shares Outstanding
Volume
Dividend Rate

Acceleron Pharma NASDAQ:XLRN is reporting this earnings, what to expect.

1 COMMENT

Comments are closed.